• Now Accepting LOIs for the MM Research Network!

    Community hospitals are invited to advance real-world multiple myeloma research by joining the Network.

    Read More
    News & Events

  • Living with Sickle Cell Disease: New Data Hub Report

    Explore real-world insights from 13,000+ people with SCD in the SCD Data Hub, shaped with guidance from our Community Advisory Board.

    Download the Report
    ASH RC Sickle Cell Disease Data Hub Report 2025 (Banner - Blue)

  • Smarter Insights. Better Care. Real-World Impact for Sickle Cell Disease

    Explore how the ASH RC Data Hub is transforming hematology research with curated real-world data, driving innovation in sickle cell disease and beyond.

    Read Article
    Slider Image 7

  • Access Resources for Clinical Trial Participants

    By participating in a clinical trial for sickle cell disease (SCD), you could help researchers learn more about the disease and create new treatments that can improve the lives of people with SCD.

    Additional Resources
    Slider Image 9

  • ASH Research Collaborative’s Real-World Evidence Consortium for SCD Goes Live with Duke Clinical Research Institute

    The Real-World Evidence Consortium aims to develop consensus recommendations on clinical outcomes to improve care for individuals living with sickle cell disease.

    Read Article
    Slideshow Real World Evidence Consortium

  • Real-World Evidence Initiative Reports Now Available

    The Real-World Evidence Initiative is excited to share the final recommendations from the Genomic Therapies and the Coordinated Registry Network Work Groups. The reports chart out a future path for regulatory science and for genomic therapies.

    Final Recommendations
    Slider Image 1

  • Connect With Us on Social Media

    Follow us on Twitter/X and Facebook as we share the latest updates from ASH RC and connect with those who are also working to improve the lives of people affected by blood diseases.

    Facebook Twitter/X
    Slider Image 8
PreviousNext
1234567

Improving Research to Build a Brighter Future for People with Hematologic Conditions

Individuals living with hematologic conditions need more evidence-based options for managing their health and improving their quality of life. The ASH Research Collaborative® (ASH RC) is working to accelerate change by making it more efficient to conduct research, from increasing access to high-quality clinical data to making it easier for individuals with hematologic conditions to participate in studies.

The ASH RC is currently focused in two disease areas: One classical hematologic condition, sickle cell disease (SCD), and one malignant hematologic disease, multiple myeloma (MM).

  • At the heart of both programs are site-based Research Networks consisting of experts in their respective fields.
  • The SCD Research Network fosters collaborative partnerships to accelerate progress in clinical research and improve outcomes for individuals living with SCD by expediting the development of therapeutics and generating high-quality evidence to support clinical decision-making. Learn about the SCD Research Network.
  • The MM Research Network is committed to building relationships within the myeloma community, leveraging the power of real-world evidence, and prioritizing research to improve the lives of individuals living with multiple myeloma. Learn about the MM Research Network.

Both Networks are powered by real-world data (RWD) which we call The Data Hub. The Data Hub is designed to be the largest shared information resource with real-world data to serve the hematology community. Access to these data can accelerate research and development, support regulatory decision-making, and help clinics identify opportunities for quality improvement. Learn about the Data Hub

ASH RC Home

Latest Announcements

News & Events

Multiple Myeloma Research

ASH Research Collaborative Multiple Myeloma Data Hub Award

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
Multiple Myeloma Investigator Initiated Research

Iron Overload Remains Prevalent in Individuals with Sickle Cell Disease Despite Diagnosis and Treatment Guidelines

New research presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, finds that iron overload is a prevalent problem for individuals receiving blood transfusions to treat their sickle cell disease.
Read more
Real-World Evidence Consortium for Sickle Cell Disease

Study Finds Potential Protective Uric Acid Range in Individuals with Sickle Cell Disease

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
Multiple Myeloma Research

Novel Technique Preserves Patient Privacy and Data Integrity Across Sickle Cell Disease Registries

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
Multiple Myeloma Research

Social Disadvantage May Drive Difference in Myeloma Outcomes

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
Sickle Cell Disease Investigator Initiated Research

Study Finds Association Between Increased Proteins in Urine and Venous Thromboembolism in Individuals With Sickle Cell Disease

The American Society of Hematology (ASH) has expanded its awards and mentorship programs to address the threats to funding for hematology research and to protect the pipeline of new hematologists entering the field. In these extraordinary times, the ASH RC is uniquely positioned to advance ASH’s Multifaceted Approach to Research and Regulatory Challenges in Hematology (MARRCH) initiative by expanding and diversifying its Multiple Myeloma (MM) Research Network.
Read more
ASH RC

ASH Research Collaborative to Present Data at 67th ASH Annual Meeting and Exposition

Presentations highlight how real-world data accelerate research and improve hematology care.
Read more
Blood Advances

Accelerating Novel Therapies for Sickle Cell Disease with RWE: ASH RC Data Hub as a Strategically Coordinated Registry Network

Real-world evidence (RWE) has been used to improve quality of care, accelerate innovation, and evaluate emerging therapies for drugs, devices, and biologics. The Coordinated Registry Network (CRN), aggregating and linking highly curated patient data, has emerged as a model for RWE generation that has guided the development of the ASH Research Collaborative® (ASH RC) Data Hub. With the aim of bolstering research, enhancing clinical care, and expediting evidence generation using RWE, ASH RC, and the Innovative Genomics Institute (IGI) launched a joint initiative, "Accelerating Innovations for Sickle Cell Disease (SCD) with Real-World Evidence," to evaluate and make recommendations to the Data Hub.
Read more
ASH Logo (SEO)

ASH Research Collaborative (ASH RC) Sickle Cell Disease (SCD) Data Hub Award  

Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
Read more
PreviousNext
123456789

Follow Us On Twitter/X

@ASHCOLLAB